Founded in 2002 as a 50:50 joint venture; Bachem AG and Berna a Crucell Company, Pevion Biotech is a Swiss developing company active in one of the fastest growing markets in the pharmaceutical industry, the vaccine field. Since its foundation as an industrial spin-off in 2002 the company has been focusing on the preclinical and clinical development of vaccines to treat and prevent infectious and chronic diseases. The target indications represent major medical needs, including breast cancer, hepatitis C, candidiasis, DiTe, RSV and malaria.